Dr. Revathy Mohan V.R., MBBS

Active Clinical Contributor & Author

Clinical Articles & Analysis by Dr. Revathy Mohan V.R., MBBS

1279 Articles

Pancreatic Adenosquamous Carcinoma Study Supports Subtype-Specific Therapy

AACR investigators profiled pancreatic adenosquamous carcinoma with clinical, genomic, and spatial transcriptomics to inform subtype-specific treatment strategies.

Oct 18, 2026

Oncology·Cancer Disc

Sarcoma Maintenance Therapy Shows Long-Term Survival With MASCT-I

Phase I data show MASCT-I maintenance was well tolerated in advanced sarcoma, with sustained antigen-specific immunity and encouraging…

Oct 18, 2026

Oncology·Cancer Disc

DNA Hypomethylating Agents May Boost CD3-Bispecific Antibody Response

Cancer Discovery abstract links DNA hypomethylating agents with preserved T-cell stemness and stronger activity of CD3-bispecific antibodies.

Oct 18, 2026

Oncology·Gut

Tumor Cell Plasticity Emerges as a Central Driver of Cancer Progression

A MedComm review frames tumor cell plasticity as a central mechanism in cancer evolution, metastasis, therapy resistance, and…

Oct 18, 2026

Oncology·Gut

ctDNA MRD testing refines recurrence risk in colorectal cancer

Prospective INTERCEPT data support ctDNA MRD as a prognostic marker in colorectal cancer, including later follow-up after surgery.

Oct 18, 2026

Oncology·JAMA Onc

SBRT emerges as a treatment option for RCC with IVC tumor thrombus

A review in Cancers examines stereotactic body radiation therapy for renal cell carcinoma with inferior vena cava tumor…

Oct 18, 2026

Oncology·JAMA Onc

Locoregional Therapy in Advanced Intrahepatic Cholangiocarcinoma Gains Clinical Attention

A narrative review examines how locoregional therapy may pair with chemotherapy, immunotherapy, and emerging cellular approaches in advanced…

Oct 18, 2026

Oncology·JAMA Onc

T-cell–Engaging Bispecific Antibodies and Second Primary Malignancies: Interpreting the Signal

JAMA Oncology reply addresses how to interpret second primary malignant neoplasms after T-cell–engaging bispecific antibody therapy using aggregate…

Oct 18, 2026

Oncology·JAMA Onc

dMMR/MSI Gastroesophageal Cancer Responds to Neoadjuvant Immunotherapy

A French case series found durable responses with neoadjuvant immunotherapy in localized dMMR/MSI gastroesophageal adenocarcinoma, including non-operative management.

Oct 18, 2026

Hematology·Blood

Germline DDX41 Marks Distinct MDS Subgroup With Better Transplant Outcomes

Germline DDX41 identifies a distinct MDS subgroup undergoing transplantation, with lower relapse and improved survival in the study…

Oct 18, 2026

Independent Review Board

All articles authored by our clinical fellows are cross-audited by MWF Review Team featuring 10 senior department chairs from premier hospitals.

Explore Review Team

In Brief The 5-minute rounds

New hypertension guideline lowers the treatment threshold to 130/80 mm Hg.
Phase 3 GLP-1 trial reports a 20% cut in major adverse cardiac events.
FDA clears a next-generation CAR-T therapy for relapsed lymphoma.
Meta-analysis links early mobilisation to shorter ICU length of stay.
Rapid guidance broadens empiric antibiotics for suspected sepsis.